% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Klotz:284632,
      author       = {D. M. Klotz$^*$ and T. Link$^*$ and P. Wimberger$^*$ and J.
                      D. Kuhlmann$^*$},
      title        = {{A} predictive and prognostic model for surgical outcome
                      and prognosis in ovarian cancer computed by
                      clinico-pathological and serological parameters ({CA}125,
                      {HE}4, mesothelin).},
      journal      = {Clinical chemistry and laboratory medicine},
      volume       = {62},
      number       = {3},
      issn         = {1434-6621},
      address      = {Berlin [u.a.]},
      publisher    = {De Gruyter},
      reportid     = {DKFZ-2023-02039},
      pages        = {530-539},
      year         = {2023},
      note         = {2023 Oct 11;62(3):530-539},
      abstract     = {Numerous prognostic models have been proposed for ovarian
                      cancer, extending from single serological factors to complex
                      gene-expression signatures. Nonetheless, these models have
                      not been routinely translated into clinical practice. We
                      constructed a robust and readily calculable model for
                      predicting surgical outcome and prognosis of ovarian cancer
                      patients by exploiting commonly available
                      clinico-pathological factors and three selected serum
                      parameters.Serum CA125, human epididymis protein 4 (HE4) and
                      mesothelin (MSL) were quantified by Lumipulse® G
                      chemiluminescent enzyme immunoassay (Fujirebio) in a total
                      of 342 serum samples from 190 ovarian cancer patients,
                      including 152 paired pre- and post-operative
                      samples.Detection of pre-operative HE4 and CA125 was the
                      optimal marker combination for blood-based prediction of
                      surgical outcome (AUC=0.86). We constructed a prognostic
                      model, computed by serum levels of pre-operative CA125,
                      post-operative HE4, post-operative MSL and surgical outcome.
                      Prognostic performance of our model was superior to any of
                      these parameters alone and was independent from BRCA1/2
                      mutational status. We subsequently transformed our model
                      into a prognostic risk index, stratifying patients as 'lower
                      risk' or 'higher risk'. In 'higher risk' patients, relapse
                      or death was predicted with an AUC of 0.89 and they had a
                      significantly shorter progression free survival (HR: 9.74;
                      95 $\%$ CI: 5.95-15.93; p<0.0001) and overall survival (HR:
                      5.62; 95 $\%$ CI: 3.16-9.99; p<0.0001) compared to 'lower
                      risk' patients.We present a robust predictive/prognostic
                      model for ovarian cancer, which could readily be implemented
                      into routine diagnostics in order to identify ovarian cancer
                      patients at high risk of recurrence.},
      keywords     = {CA125 (Other) / HE4 (Other) / mesothelin (Other) / ovarian
                      cancer (Other) / prognostic model (Other)},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37816681},
      doi          = {10.1515/cclm-2023-0314},
      url          = {https://inrepo02.dkfz.de/record/284632},
}